(Q43690830)

25 November 2017

title

Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol (English)

1 reference

25 November 2017

1 reference

1 reference

1

Louis J Ignarro

1 reference

25 November 2017

publication date

1 January 2008

1 reference

Cardiovascular Therapeutics

25 November 2017

published in

1 reference

25 November 2017

volume

26

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

115-134

1 reference

Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nitric oxide mediated venodilator effects of nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Effects of nebivolol on human platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Different effect of antihypertensive drugs on conduit artery endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

In vivo EDRF activity influences platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol is devoid of intrinsic sympathomimetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Structure-activity relationships as a response to the pharmacological differences in beta-receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Effects of beta-adrenoceptor antagonists on cardiac function in ischemic-reperfused myocardium of the isolated working rabbit heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol: a review of its use in the management of hypertension and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Stereochemical comparison of nebivolol with other beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol decreases systemic oxidative stress in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2008.00044.X

Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Cubic (In,Ga)N layers grown on GaAs(001) by dc plasma-assisted molecular beam epitaxy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Effects of D-Nebivolol and L-Nebivolol on Left Ventricular Systolic and Diastolic Function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

ENOS is not activated by nebivolol in human failing myocardium

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Vasodilator effect of tertatolol in isolated perfused rat kidneys: involvement of endothelial 5-HT1A receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide‐mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Characterization of Nitric Oxide Release by Nebivolol and Its Metabolites

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/J.1527-3466.2008.00044.X

Identifiers

DOI

10.1111/J.1527-3466.2008.00044.X

1 reference

25 November 2017

1 reference